Angiogenesis-regulating microRNAs and ischemic stroke

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 352-365

  Yin, Ke Jie ^a   Hamblin, Milton ^b   Chen, Y Eugene ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiogenesis regulating microRNAs (angiomiRs); Angiogenic factors; Cerebrovascular diseases; Ischemic stroke; MicroRNAs; Neurovascular unit; Vascular endothelial cells

Indexed keywords

ANGIOGENIC FACTOR; ANGIOMIR; ANGIOMIR INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MICRORNA 126; MICRORNA 130A; MICRORNA 132; MICRORNA 145; MICRORNA 15; MICRORNA 15A; MICRORNA 16; MICRORNA 181; MICRORNA 200B; MICRORNA 21; MICRORNA 210; MICRORNA 217; MICRORNA 221; MICRORNA 222; MICRORNA 23A; MICRORNA 296; MICRORNA 29B; MICRORNA 31; MICRORNA 320; MICRORNA 320A; MICRORNA 378; MICRORNA 424; MICRORNA 497; MICRORNA 503; MICRORNA 92A; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; BRAIN REGION; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; MICROARRAY ANALYSIS; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; ANIMAL; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; BRAIN ISCHEMIA; HUMANS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; STROKE;

EID: 84937117366     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990016     Document Type: Article

References (202)

1. [1] Schellinger PD, Kaste M, Hacke W. An update on thrombolytic therapy for acute stroke. Curr Opin Neurol 2004; 17(1): 69-77.
2. [2] Schellinger PD, Warach S. Therapeutic time window of thrombolytic therapy following stroke. Current atherosclerosis reports 2004; 6(4): 288-94.
3. [3] Stapf C, Mohr JP. Ischemic stroke therapy. Annual review of medicine 2002; 53: 453-75.
4. [4] Barone FC. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr Opin Investig Drugs 2009; 10(3): 220-3.
5. [5] del Zoppo GJ. Stroke and neurovascular protection. The New England journal of medicine 2006; 354(6): 553-5.
6. [6] Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009; 40(3 Suppl): S111-4.
7. [7] Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4(5): 399-415.
8. [8] Lok J, Gupta P, Guo S, et al. Cell-cell signaling in the neurovascular unit. Neurochem Res 2007; 32(12): 2032-45.
9. [9] Yuan J. Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke. Apoptosis 2009; 14(4): 469-77.
10. [10] Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5(5): 347-60.
11. [11] Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57(2): 178-201.
12. [12] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
13. [13] Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438(7070): 932-6.
14. [14] Hayashi T, Deguchi K, Nagotani S, et al. Cerebral ischemia and angiogenesis. Curr Neurovasc Res 2006; 3(2): 119-29.
15. [15] Beck H, Plate KH. Angiogenesis after cerebral ischemia. Acta Neuropathol 2009; 117(5): 481-96.
16. [16] Arai K, Jin G, Navaratna D, Lo EH. Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J 2009; 276(17): 4644-52.
17. [17] Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol 2009; 8(5): 491-500.
18. [18] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
19. [19] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
20. [20] Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6(5): 376-85.
21. [21] Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004; 5(5): 396-400.
22. [22] Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001; 15(20): 2654-9.
23. [23] Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23(20): 4051-60.
24. [24] Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005; 579(26): 5911-22.
25. [25] Wang S, Olson EN. AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev 2009; 19(3): 205-11.
26. [26] Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008; 29(1): 12-5.
27. [27] Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009; 104(4): 442-54.
28. [28] Hebert SS, Horre K, Nicolai L, et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis 2009; 33(3): 422-8.
29. [29] Hebert SS, Horre K, Nicolai L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008; 105(17): 6415-20.
30. [30] Kim J, Inoue K, Ishii J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007; 317(5842): 1220-4.
31. [31] Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008; 82(2): 283-9.
32. [32] Williams AH, Valdez G, Moresi V, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009; 326(5959): 1549-54.
33. [33] Liu NK, Wang XF, Lu QB, Xu XM. Altered microRNA expression following traumatic spinal cord injury. Exp Neurol 2009; 219(2): 424-9.
34. [34] Redell JB, Liu Y, Dash PK. Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes. J Neurosci Res 2009; 87(6): 1435-48.
35. [35] Nicoloso MS, Calin GA. MicroRNA involvement in brain tumors: from bench to bedside. Brain Pathol 2008; 18(1): 122-9.
36. [36] Beveridge NJ, Tooney PA, Carroll AP, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008; 17(8): 1156-68.
37. [37] Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke 2008; 39(3): 959-66.
38. [38] Dharap A, Bowen K, Place R, Li LC, Vemuganti R. Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. J Cereb Blood Flow Metab 2009; 29(4): 675-87.
39. [39] Yin KJ, Deng Z, Hamblin M, et al. Peroxisome proliferatoractivated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci 2010; 30(18): 6398-408.
40. [40] Yin KJ, Deng Z, Huang H, et al. miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. Neurobiol Dis 2010; 38(1): 17-26.
41. [41] Lusardi TA, Farr CD, Faulkner CL, et al. Ischemic preconditioning regulates expression of microRNAs and a predicted target, MeCP2, in mouse cortex. J Cereb Blood Flow Metab 2010; 30(4): 744-56.
42. [42] Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101(1): 59-68.
43. [43] Suarez Y, Fernandez-Hernando C, Yu J, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 2008; 105(37): 14082-7.
44. [44] Beck H, Acker T, Wiessner C, Allegrini PR, Plate KH. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. Am J Pathol 2000; 157(5): 1473-83.
45. [45] Hayashi T, Noshita N, Sugawara T, Chan PH. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J Cereb Blood Flow Metab 2003; 23(2): 166-80.
46. [46] Marti HJ, Bernaudin M, Bellail A, et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 2000; 156(3): 965-76.
47. [47] Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994; 25(9): 1794-8.
48. [48] Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Some remarks on the growth-rate and angiogenesis of microvessels in ischemic stroke. Morphometric and immunocytochemical studies. Patol Pol 1993; 44(4): 203-9.
49. [49] Lennmyr F, Ata KA, Funa K, Olsson Y, Terent A. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol 1998; 57(9): 874-82.
50. [50] Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest 1999; 79(4): 417-25.
51. [51] Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 1996; 27(10): 1865-72; discussion 72-3.
52. [52] Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005; 438(7070): 954-9.
53. [53] Hayashi T, Abe K, Suzuki H, Itoyama Y. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 1997; 28(10): 2039-44.
54. [54] Plate KH, Beck H, Danner S, Allegrini PR, Wiessner C. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. Journal of neuropathology and experimental neurology 1999; 58(6): 654-66.
55. [55] Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106(7): 829-38.
56. [56] Sun Y, Jin K, Xie L, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111(12): 1843-51.
57. [57] Wang Y, Kilic E, Kilic U, et al. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 2005; 128(Pt 1): 52-63.
58. [58] Cobbs CS, Chen J, Greenberg DA, Graham SH. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat. Neurosci Lett 1998; 249(2-3): 79-82.
59. [59] Lee MY, Ju WK, Cha JH, et al. Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats. Neurosci Lett 1999; 265(2): 107-10.
60. [60] Gunsilius E, Petzer AL, Stockhammer G, Kahler CM, Gastl G. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 2001; 32(1): 275-8.
61. [61] Slevin M, Krupinski J, Slowik A, Kumar P, Szczudlik A, Gaffney J. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 2000; 31(8): 1863-70.
62. [62] Lin TN, Te J, Lee M, Sun GY, Hsu CY. Induction of basic fibroblast growth factor (bFGF) expression following focal cerebral ischemia. Brain Res 1997; 49(1-2): 255-65.
63. [63] Chen HH, Chien CH, Liu HM. Correlation between angiogenesis and basic fibroblast growth factor expression in experimental brain infarct. Stroke 1994; 25(8): 1651-7.
64. [64] Issa R, AlQteishat A, Mitsios N, et al. Expression of basic fibroblast growth factor mRNA and protein in the human brain following ischaemic stroke. Angiogenesis 2005; 8(1): 53-62.
65. [65] Iihara K, Sasahara M, Hashimoto N, Hazama F. Induction of platelet-derived growth factor beta-receptor in focal ischemia of rat brain. J Cereb Blood Flow Metab 1996; 16(5): 941-9.
66. [66] Iihara K, Sasahara M, Hashimoto N, Uemura Y, Kikuchi H, Hazama F. Ischemia induces the expression of the platelet-derived growth factor-B chain in neurons and brain macrophages in vivo. J Cereb Blood Flow Metab 1994; 14(5): 818-24.
67. [67] Kawabe T, Wen TC, Matsuda S, Ishihara K, Otsuda H, Sakanaka M. Platelet-derived growth factor prevents ischemia-induced neuronal injuries in vivo. Neurosci Res 1997; 29(4): 335-43.
68. [68] Renner O, Tsimpas A, Kostin S, et al. Time-and cell type-specific induction of platelet-derived growth factor receptor-beta during cerebral ischemia. Brain Res 2003; 113(1-2): 44-51.
69. [69] Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6: 597-641.
70. [70] Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83(12): 4167-71.
71. [71] Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111(2): 731-41.
72. [72] Wiessner C, Gehrmann J, Lindholm D, Topper R, Kreutzberg GW, Hossmann KA. Expression of transforming growth factor-beta 1 and interleukin-1 beta mRNA in rat brain following transient forebrain ischemia. Acta Neuropathol 1993; 86(5): 439-46.
73. [73] Yamashita K, Gerken U, Vogel P, Hossmann K, Wiessner C. Biphasic expression of TGF-beta1 mRNA in the rat brain following permanent occlusion of the middle cerebral artery. Brain Res 1999; 836(1-2): 139-45.
74. [74] Haqqani AS, Nesic M, Preston E, Baumann E, Kelly J, Stanimirovic D. Characterization of vascular protein expression patterns in cerebral ischemia/reperfusion using laser capture microdissection and ICAT-nanoLC-MS/MS. FASEB J 2005; 19(13): 1809-21.
75. [75] Krupinski J, Kumar P, Kumar S, Kaluza J. Increased expression of TGF-beta 1 in brain tissue after ischemic stroke in humans. Stroke 1996; 27(5): 852-7.
76. [76] Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2(7): 502-11.
77. [77] Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
78. [78] Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115(Pt 19): 3719-27.
79. [79] Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92(8): 827-39.
80. [80] Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20(12): 1681-9.
81. [81] Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 2001; 12(13): 3003-7.
82. [82] Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of bloodbrain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21(19): 7724-32.
83. [83] Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995; 26(11): 2120-6.
84. [84] Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996; 16(6): 1373-8.
85. [85] Hamann GF, Liebetrau M, Martens H, et al. Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 2002; 22(5): 526-33.
86. [86] Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576(2): 203-7.
87. [87] Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995; 12(5): 833-42.
88. [88] Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18(11): 1163-72.
89. [89] Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 1998; 274(5 Pt 2): R1203-11.
90. [90] Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29(10): 2189-95.
91. [91] Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31(12): 3034-40.
92. [92] Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33(3): 831-6.
93. [93] Montaner J, Alvarez-Sabin J, Molina CA, et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32(12): 2762-7.
94. [94] Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107(4): 598-603.
95. [95] Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12(4): 441-5.
96. [96] Lin TN, Kim GM, Chen JJ, Cheung WM, He YY, Hsu CY. Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 2003; 34(1): 177-86.
97. [97] Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3(3): 411-23.
98. [98] Lin TN, Wang CK, Cheung WM, Hsu CY. Induction of angiopoietin and Tie receptor mRNA expression after cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2000; 20(2): 387-95.
99. [99] Zhang Z, Chopp M. Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med 2002; 12(2): 62-6.
100. [100] Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res 2002; 90(3): 284-8.
101. [101] Zhang ZG, Zhang L, Tsang W, et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 2002; 22(4): 379-92.
102. [102] Zhang ZG, Chopp M, Lu D, Wayne T, Zhang RL, Morris D. Receptor tyrosine kinase tie 1 mRNA is upregulated on cerebral microvessels after embolic middle cerebral artery occlusion in rat. Brain Res 1999; 847(2): 338-42.
103. [103] Veltkamp R, Rajapakse N, Robins G, Puskar M, Shimizu K, Busija D. Transient focal ischemia increases endothelial nitric oxide synthase in cerebral blood vessels. Stroke 2002; 33(11): 2704-10.
104. [104] Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-Larginine. J Cereb Blood Flow Metab 1996; 16(5): 981-7.
105. [105] Chen J, Zacharek A, Zhang C, et al. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci 2005; 25(9): 2366-75.
106. [106] Beck H, Acker T, Puschel AW, Fujisawa H, Carmeliet P, Plate KH. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol 2002; 61(4): 339-50.
107. [107] Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002; 85(2): 357-68.
108. [108] MacGabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol 2007; 292(1): H459-74.
109. [109] Zhang ZG, Tsang W, Zhang L, Powers C, Chopp M. Up-regulation of neuropilin-1 in neovasculature after focal cerebral ischemia in the adult rat. J Cereb Blood Flow Metab 2001; 21(5): 541-9.
110. [110] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843-54.
111. [111] Ambros V. The functions of animal microRNAs. Nature 2004; 431(7006): 350-5.
112. [112] Wienholds E, Kloosterman WP, Miska E, et al. MicroRNA expression in zebrafish embryonic development. Science 2005; 309(5732): 310-1.
113. [113] Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13(5): 613-8.
114. [114] Krutzfeldt J, Stoffel M. MicroRNAs: a new class of regulatory genes affecting metabolism. Cell Metab 2006; 4(1): 9-12.
115. [115] Sullivan CS, Ganem D. MicroRNAs and viral infection. Mol Cell 2005; 20(1): 3-7.
116. [116] Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature 2005; 435(7042): 682-6.
117. [117] Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007; 43(10): 1529-44.
118. [118] Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38(9): 1060-5.
119. [119] O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435(7043): 839-43.
120. [120] Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103(7): 2257-61.
121. [121] He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435(7043): 828-33.
122. [122] Urbich C, Kaluza D, Fromel T, et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012; 119(6): 1607-16.
123. [123] Biyashev D, Veliceasa D, Topczewski J, et al. miR-27b controls venous specification and tip cell fate. Blood 2012; 119(11): 2679-87.
124. [124] Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15(2): 272-84.
125. [125] Kuhnert F, Mancuso MR, Hampton J, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008; 135(24): 3989-93.
126. [126] Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008; 105(5): 1516-21.
127. [127] Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111(3): 1217-26.
128. [128] Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283(23): 15878-83.
129. [129] Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 2008; 582(16): 2397-401.
130. [130] Liu F, Lou YL, Wu J, et al. Upregulation of MicroRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res 2012; 35(3): 182-91.
131. [131] Wurdinger T, Tannous BA, Saydam O, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008; 14(5): 382-93.
132. [132] Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 2007; 104(51): 20350-5.
133. [133] Tsai YH, Wu MF, Wu YH, et al. The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. J Virol 2009; 83(2): 622-32.
134. [134] Liu LZ, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One 2011; 6(4): e19139.
135. [135] Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez-Hernando C, Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol 2011; 31(11): 2595-606.
136. [136] Yin KJ, Olsen K, Hamblin M, Zhang J, Schwendeman SP, Chen YE. Vascular Endothelial Cell-specific MicroRNA-15a Inhibits Angiogenesis in Hindlimb Ischemia. J Biol Chem 2012; 287(32): 27055-64.
137. [137] Gatt ME, Zhao JJ, Ebert MS, et al. MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood 2010; doi: 10.1182/blood-2009-11-253294.
138. [138] Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006; 1: e116.
139. [139] Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA 2009; 15(2): 249-54.
140. [140] Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108(9): 3068-71.
141. [141] Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007; 100(8): 1164-73.
142. [142] Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324(5935): 1710-3.
143. [143] Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2009; 36(2): 181-8.
144. [144] Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011; 286(3): 2047-56.
145. [145] Menghini R, Casagrande V, Cardellini M, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009; 120(15): 1524-32.
146. [146] Caporali A, Emanueli C. MicroRNA-503 and the Extended MicroRNA-16 Family in Angiogenesis. Trends in cardiovascular medicine 2011; 21(6): 162-6.
147. [147] Caporali A, Meloni M, Vollenkle C, et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011; 123(3): 282-91.
148. [148] Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab 2010; 299(1): E110-6.
149. [149] Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 2010; 398(4): 735-40.
150. [150] Shih TC, Tien YJ, Wen CJ, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol 2012; 57(3): 584-91.
151. [151] van Mil A, Grundmann S, Goumans MJ, et al. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res 2012; 93(4): 655-65.
152. [152] Chan LS, Yue PY, Mak NK, Wong RN. Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur J Pharm Sci 2009; 38(4): 370-7.
153. [153] Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15(2): 261-71.
154. [154] Kosik KS. The neuronal microRNA system. Nat Rev Neurosci 2006; 7(12): 911-20.
155. [155] Jeyaseelan K, Herath WB, Armugam A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets 2007; 11(8): 1119-29.
156. [156] Lee ST, Chu K, Jung KH, et al. MicroRNAs induced during ischemic preconditioning. Stroke 2010; 41(8): 1646-51.
157. [157] Dharap A, Vemuganti R. Ischemic pre-conditioning alters cerebral microRNAs that are upstream to neuroprotective signaling pathways. J Neurochem 2010; 113(6): 1685-91.
158. [158] Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100(11): 1579-88.
159. [159] Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009; 104(4): 476-87.
160. [160] Zhang C. MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle 2009; 8(21): 3469-73.
161. [161] Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009; 105(2): 158-66.
162. [162] Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460(7256): 705-10.
163. [163] Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23(18): 2166-78.
164. [164] Santovito D, Mezzetti A, Cipollone F. MicroRNAs and atherosclerosis: New actors for an old movie. Nutr Metab Cardiovasc Dis 2012; 22(11): 937-43.
165. [165] Rink C, Khanna S. MicroRNA in ischemic stroke etiology and pathology. Physiol Genomics 2011; 43(10): 521-8.
166. [166] Tan JR, Koo YX, Kaur P, et al. microRNAs in stroke pathogenesis. Curr Mol Med 2011; 11(2): 76-92.
167. [167] Raitoharju E, Lyytikainen LP, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011; 219(1): 211-7.
168. [168] Cipollone F, Felicioni L, Sarzani R, et al. A unique microRNA signature associated with plaque instability in humans. Stroke 2011; 42(9): 2556-63.
169. [169] Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148(6): 1172-87.
170. [170] Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, Ivan M. Regulation of microRNA expression: the hypoxic component. Cell Cycle 2007; 6(12): 1426-31.
171. [171] Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27(5): 1859-67.
172. [172] Crosby ME, Devlin CM, Glazer PM, Calin GA, Ivan M. Emerging roles of microRNAs in the molecular responses to hypoxia. Curr Pharm Des 2009; 15(33): 3861-6.
173. [173] Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009; 69(3): 1221-9.
174. [174] Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther 2010; 125(1): 92-104.
175. [175] Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55(11): 1977-83.
176. [176] Liu DZ, Tian Y, Ander BP, et al. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab 2010; 30(1): 92-101.
177. [177] Weng H, Shen C, Hirokawa G, et al. Plasma miR-124 as a biomarker for cerebral infarction. Biomed Res 2011; 32(2): 135-41.
178. [178] Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of MicroRNAs in young stroke patients. PLoS One 2009; 4(11): e7689.
179. [179] Gan CS, Wang CW, Tan KS. Circulatory microRNA-145 expression is increased in cerebral ischemia. Genet Mol Res 2012; 11(1): 147-52.
180. [180] Zeng L, Liu J, Wang Y, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011; 3: 1265-72.
181. [181] Sepramaniam S, Armugam A, Lim KY, et al. MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. J Biol Chem 2010; 285(38): 29223-30.
182. [182] Buller B, Liu X, Wang X, et al. MicroRNA-21 protects neurons from ischemic death. FEBS J 2010; 277(20): 4299-307.
183. [183] Siegel C, Li J, Liu F, Benashski SE, McCullough LD. miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. Proc Natl Acad Sci USA 2011; 108(28): 11662-7.
184. [184] Ouyang YB, Lu Y, Yue S, et al. miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. Neurobiol Dis 2012; 45(1): 555-63.
185. [185] Shi G, Liu Y, Liu T, et al. Upregulated miR-29b promotes neuronal cell death by inhibiting Bcl2L2 after ischemic brain injury. Exp Brain Res 2012; 216(2): 225-30.
186. [186] Selvamani A, Sathyan P, Miranda RC, Sohrabji F. An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS One 2012; 7(2): e32662.
187. [187] Hunsberger JG, Fessler EB, Wang Z, Elkahloun AG, Chuang DM. Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res 2012; 4(3): 316-32.
188. [188] Zhang L, Chopp M, Liu X, et al. Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway. Arterioscler Thromb Vasc Biol 2012; 32(8): 1856-64.
189. [189] Park HA, Kubicki N, Gnyawali S, et al. Natural vitamin E alphatocotrienol protects against ischemic stroke by induction of multidrug resistance-associated protein 1. Stroke 2011; 42(8): 2308-14.
190. [190] Liu XS, Chopp M, Zhang RL, et al. MicroRNA profiling in subventricular zone after stroke: MiR-124a regulates proliferation of neural progenitor cells through Notch signaling pathway. PLoS One 2011; 6(8): e23461.
191. [191] Saugstad JA. MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J Cereb Blood Flow Metab 2010; 30(9): 1564-76.
192. [192] Vemuganti R. The MicroRNAs and Stroke: No Need to be Coded to be Counted. Transl Stroke Res 2010; 1(3): 158-60.
193. [193] Lou YL, Guo F, Liu F, et al. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem 2012; 370(1-2): 45-51.
194. [194] van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103(9): 919-28.
195. [195] Latronico MV, Condorelli G. Therapeutic use of microRNAs in myocardial diseases. Curr Heart Fail Rep 2011; 8(3): 193-7.
196. [196] Port JD, Sucharov C. Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials. J Cardiovasc Pharmacol 2010; 56(5): 444-53.
197. [197] Doebele C, Bonauer A, Fischer A, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010; 115(23): 4944-50.
198. [198] Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438(7068): 685-9.
199. [199] Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327(5962): 198-201.
200. [200] Porrello ER, Johnson BA, Aurora AB, et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res 2011; 109(6): 670-9.
201. [201] Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43(4): 371-8.
202. [202] Lu Y, Xiao J, Lin H, et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 2009; 37(3): e24.